We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ICON PLC | NASDAQ:ICLR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.73 | 1.25% | 301.61 | 301.38 | 303.31 | 306.40 | 296.5725 | 297.27 | 357,008 | 23:43:21 |
ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 23, 2019 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 10, 2019 and are available on the ICON plc website.
The final results of the voting are as follows:
RESOLUTION NUMBER
RESOLUTION
TOTAL NUMBER OF VOTES
VOTE FOR
VOTE AGAINST
VOTE WITHHELD
1.1
To re-elect Dr. John Climax
45,426,638
45,129,835
287,973
8,830
1.2
To re-elect Dr. Steve Cutler
45,426,638
45,254,223
163,617
8,798
1.3
To re-elect Professor William Hall
45,426,638
44,903,508
514,140
8,990
2
To receive accounts and reports
45,426,638
45,274,969
15,009
136,660
3
To authorise the fixing of the auditors’ remuneration
45,426,638
42,524,937
2,895,529
6,172
4
To authorise the Company to allot shares
45,426,638
44,465,330
951,583
9,725
5**
To disapply pre-emption rights
45,426,638
43,247,089
2,157,812
21,737
6**
To disapply pre-emption rights for funding capital investment or acquisitions
45,426,638
43,249,638
2,156,336
20,664
7**
To authorise the Company to make market purchases of shares
45,426,638
45,231,479
36,310
158,849
8**
To authorise the price range at which the Company can reissue shares it holds as treasury shares
45,426,638
45,135,367
126,751
164,520
** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON employed approximately 14,400 employees in 98 locations in 40 countries as at June 30, 2019. Further information is available at www.iconplc.com.
Source: ICON plc
All at ICON.
ICON/ICLR-F
View source version on businesswire.com: https://www.businesswire.com/news/home/20190724005303/en/
Investor Relations 1 888 381 7923 or Brendan Brennan Chief Financial Officer + 353 1 291 2000
Jonathan Curtain Vice President Corporate Finance and Investor Relations + 353 1 291 2000
1 Year ICON Chart |
1 Month ICON Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions